Clinical Trials Logo

Recurrent Bladder Cancer clinical trials

View clinical trials related to Recurrent Bladder Cancer.

Filter by:

NCT ID: NCT04917809 Recruiting - Bladder Cancer Clinical Trials

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Start date: February 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus Calmette-Guerin (BCG) or chemotherapy instilled into the bladder. Participants in this study will have bladder cancer with a mutation in the FGFR3 gene. FGFR3 mutations are the most common genetic alteration in NMIBC and is present in the majority of recurrent NMIBC tumors. Genetic testing of the participant's prior or recurrent NMIBC tumor will be performed to confirm it has an FGFR3 gene mutation. Erdafitinib is a pill given orally (by mouth) that blocks the protein made by this altered gene, which may stop cancer cells from growing. Erdafitinib is already used as an approved treatment for metastatic bladder cancer. Researchers are doing this study to determine whether erdafitinib is an effective treatment for FGFR3-altered non-muscle invasive bladder cancer in the time period between when a recurrent tumor is identified and a TURBT (transurethral resection of a bladder tumor) or biopsy procedure is performed to remove it.

NCT ID: NCT03801278 No longer available - Clinical trials for Recurrent Bladder Cancer

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

FPA144
Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer

NCT ID: NCT03174912 Completed - Bladder Cancer Clinical Trials

In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?

Start date: January 1, 2007
Phase: Phase 4
Study type: Interventional

Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive bladder cancer patients(NMIBC), and those not treated with BCG and treated with BCG separately.

NCT ID: NCT02252393 Withdrawn - Clinical trials for Recurrent Bladder Cancer

Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer

Start date: October 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer. Radical cystectomy is surgery to remove the entire bladder as well as nearby tissues and organs. After the bladder is removed, urinary diversion (a surgical procedure to make a new way for urine to leave the body) is performed. It is not yet known whether intracorporeal (within the body) or extracorporeal (outside of the body) urinary diversion is a better method in patients with bladder cancer undergoing robotic assisted radical cystectomy.

NCT ID: NCT02122172 Terminated - Clinical trials for Stage IV Bladder Cancer

Afatinib in Advanced Refractory Urothelial Cancer

Start date: September 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

NCT ID: NCT01846520 Completed - Clinical trials for Psychosocial Effects of Cancer and Its Treatment

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

NCT ID: NCT01828736 Completed - Clinical trials for Stage IV Bladder Cancer

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma

CVH-CT02
Start date: February 9, 2004
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, Phase 2 trial to study the effectiveness and feasibility of association of trastuzumab with combination chemotherapy in advanced or metastatic bladder cancer patients. Combining monoclonal antibody therapy with combination chemotherapy may improve treatment efficacy on tumours overexpressed HER 2.

NCT ID: NCT01639521 Withdrawn - Clinical trials for Transitional Cell Carcinoma of the Bladder

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer. Both study drug regimens, gemcitabine (gemcitabine hydrochloride) plus cisplatin, and high-dose-intensity MVAC (methotrexate, vinblastine, doxorubicin plus cisplatin), are standard chemotherapy regimens. Both regimens are used to treat people with urothelial cancer that has spread to other organs. Both study drug regimens have been proven to be effective in lowering the risk of the cancer coming back, but it is not known which regimen is the best. This study hopes to learn whether there is a difference in the effectiveness and side effects of these two study drug regimens when they are given to people who have had their urothelial cancer completely removed.

NCT ID: NCT01382706 Terminated - Clinical trials for Stage IV Bladder Cancer

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Start date: June 13, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells.

NCT ID: NCT01118351 Terminated - Clinical trials for Transitional Cell Carcinoma of the Bladder

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients with recurrent transitional cell bladder cancer.